![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CytoDyn’s Leronlimab Shows No Benefit for COVID-19 Infection, Says FDA
CytoDyn’s Leronlimab Shows No Benefit for COVID-19 Infection, Says FDA
![FDA logo blue](https://www.fdanews.com/ext/resources/test/Drug-Images4/FDA_Logo_Blue.gif?t=1614197109&width=430)
May 20, 2021
The FDA has refuted CytoDyn’s claims about the efficacy of the company’s experimental HIV drug leronlimab as a COVID-19 treatment based on data from two late-stage trials.
The FDA’s rebuke followed months of CytoDyn’s CEO Nader Pourhassan repeatedly offering statements about the therapy in press releases and interviews touting the therapy’s benefits.
In a rare direct statement posted online,the agency said data from two phase 3 trials showed the monoclonal antibody offered no benefit for treating mild-to-moderate and severe COVID-19 infections and that the drug was no more effective than a placebo.
“With the conclusion of [the two] clinical trials, it has become clear that the data currently available do not support the clinical benefit of leronlimab for the treatment of COVID-19,” the agency said.
Upcoming Events
-
21Oct